Alnylam Pharmaceuticals (Alnylam Pharmaceuticals) Interest Coverage

: 0 (At Loss) (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Alnylam Pharmaceuticals's Operating Income for the three months ended in Dec. 2023 was $-116 Mil. Alnylam Pharmaceuticals's Interest Expense for the three months ended in Dec. 2023 was $-31 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Alnylam Pharmaceuticals's Interest Coverage or its related term are showing as below:

ALNY's Interest Coverage is not ranked ^*
in the Biotechnology industry.
Industry Median: 144.99
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Alnylam Pharmaceuticals Interest Coverage Historical Data

The historical data trend for Alnylam Pharmaceuticals's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Alnylam Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Coverage

N/A

Alnylam Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Coverage																-	-	-	6.92	-

Competitive Comparison

For the Biotechnology subindustry, Alnylam Pharmaceuticals's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alnylam Pharmaceuticals Interest Coverage Distribution

For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Alnylam Pharmaceuticals's Interest Coverage falls into.

Alnylam Pharmaceuticals Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Alnylam Pharmaceuticals's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Alnylam Pharmaceuticals's Interest Expense was $-121 Mil. Its Operating Income was $-282 Mil. And its Long-Term Debt & Capital Lease Obligation was $1,264 Mil.

Alnylam Pharmaceuticals did not have earnings to cover the interest expense.

Alnylam Pharmaceuticals's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Here, for the three months ended in Dec. 2023, Alnylam Pharmaceuticals's Interest Expense was $-31 Mil. Its Operating Income was $-116 Mil. And its Long-Term Debt & Capital Lease Obligation was $1,264 Mil.

Alnylam Pharmaceuticals did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's Financial Strength is.

Alnylam Pharmaceuticals (NAS:ALNY) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

Alnylam Pharmaceuticals Interest Coverage Related Terms

Thank you for viewing the detailed overview of Alnylam Pharmaceuticals's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

Alnylam Pharmaceuticals (Alnylam Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alnylam Pharmaceuticals Inc (NAS:ALNY) » Definitions » Interest Coverage

Comparable Companies

Traded in Other Exchanges

ALNY:Mexico DUL:Germany DUL:Germany

Address

675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, USA, 02142

Website

https://www.alnylam.com

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Executives

Michael W Bonney	director	65 HAYDEN AVE, LEXINGTON MA 02421
Pushkal Garg	officer: CMO & EVP Dev & Med Affairs	C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
Akshay Vaishnaw	officer: SVP, Clinical Research	300 THIRD STREET, CAMBRIDGE MA 02139
Yvonne Greenstreet	officer: EVP, Chief Commercial Officer	PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, PARSIPPANY NJ 07054
Jeffrey V. Poulton	officer: Chief Financial Officer	300 THIRD STREET, CAMBRIDGE MA 02142
Tolga Tanguler	officer: EVP, Chief Commercial Officer	675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE MA 02142
Indrani Lall Franchini	officer: EVP, CLO & Secretary	C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510
Peter N Kellogg	director	MERCK & CO., INC, ONE MERCK DRIVE., P.O. BOX 100, WHITEHOUSE STATION NJ 08889-0100
Carolyn R Bertozzi	director	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Dennis A Ausiello	director	PFIZER INC ATTN CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Charles Elliott Sigal	director	32 BREARLY ROAD, PRINCETON NJ 08540
Phillip A Sharp	director	BIOGEN INC LEGAL DEPARTMENT, 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
John Maraganore	director, officer: President and CEO	75 SIDNEY ST, CAMBRIDGE MA 02139
Laurie Keating	officer: SVP,GC & Secretary	300 THIRD STREET, CAMBRIDGE MA 02142
Steven M Paul	director	C/O ELI LITTY & CO, LIIY CORPORATE CENTER DC 1093, INDIANAPOLIS IN 46285